The APHB chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the APHB chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The APHB stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View APHB Detailed Price Forecast - CNN Money||View APHB Detailed Summary - Google Finance|
|View APHB Detailed Summary - Yahoo! Finance||View APHB Stock Research & Analysis - Zacks.com|
|View APHB Trends & Analysis - Trade-Ideas||View APHB Major Holders - Barrons|
|View APHB Call Transcripts - NASDAQ||View APHB Breaking News & Analysis - Seeking Alpha|
|View APHB Annual Report - CompanySpotlight.com||View APHB OTC Short Report - OTCShortReport.com|
|View APHB Fundamentals - TradeKing||View APHB SEC Filings - Bar Chart|
|View Historical Prices for APHB - The WSJ||View Performance/Total Return for APHB - Morningstar|
|View the Analyst Estimates for APHB - MarketWatch||View the Earnings History for APHB - CNBC|
|View the APHB Earnings - StockMarketWatch||View APHB Buy or Sell Recommendations - MacroAxis|
|View the APHB Bullish Patterns - American Bulls||View APHB Short Pain Metrics - ShortPainBot.com|
|View APHB Stock Mentions - StockTwits||View APHB Stock Mentions - PennyStockTweets|
|View APHB Stock Mentions - Twitter||View APHB Investment Forum News - Investor Hub|
|View APHB Stock Mentions - Yahoo! Message Board||View APHB Stock Mentions - Seeking Alpha|
|View Insider Transactions for APHB - SECform4.com||View Insider Transactions for APHB - Insider Cow|
|View APHB Major Holdings Summary - CNBC||View Insider Disclosure for APHB - OTC Markets|
|View Insider Transactions for APHB - Yahoo! Finance||View Institutional Holdings for APHB - NASDAQ|
|View APHB Stock Insight & Charts - FinViz.com||View APHB Investment Charts - StockCharts.com|
|View APHB Stock Overview & Charts - BarChart||View APHB User Generated Charts - Trading View|
4 Healthcare Stocks To Watch On Friday (1/4/19)
Posted on Friday January 04, 2019
CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. Premier Health Group (PHGRF) (PHGI), Flex Pharma, Inc. (NASDAQ: FLKS), Ampliphi Biosciences Corp (NYSE American: APHB), and Histogenics Corp (NASDAQ: HSGX) are 4 healthcare stocks worth checking out on Friday. Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Thursday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share.
AmpliPhi Biosciences and C3J Therapeutics Agree to Merge
Posted on Friday January 04, 2019
AmpliPhi Biosciences Corporation (“AmpliPhi”) (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and C3J Therapeutics, Inc. (“C3J”), a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials, today announced that the companies have entered into a definitive agreement under which a wholly owned subsidiary of AmpliPhi will merge with C3J in an all-stock transaction, subject to shareholder approval. The consummation of the merger transaction will result in a combined company that has a diverse clinical-stage pipeline, including a Phase 1/2-ready natural phage candidate targeting bacteremia, as well as a synthetic phage candidate targeting respiratory infections poised to enter Phase 1 development later this year.
AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development
Posted on Tuesday December 18, 2018
AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced a 10-fold increase in yield from its manufacturing process, the result of a continuous and ongoing effort to enhance manufacturing efficiencies for AB-SA01, the company’s clinical stage lead drug product candidate. AB-SA01 is a targeted bacteriophage therapeutic in clinical development for the treatment of serious and life-threatening S. aureus infections, including those that do not respond to antibiotic therapy.
APHB: Phase 2 Trial of AB-SA01 in Bacteremia to Initiate 1H19…
Posted on Thursday November 29, 2018
On October 8, 2018, AmpliPhi Biosciences Corp. (APHB) announced the presentation of data on the company’s expanded access program for AB-SA01 at IDWeek 2018. The presentation “Adjunctive bacteriophage therapy for sever Staphylococcal sepsis” was given by Prof. Jonathan Iredell, Senior Staff Infectious Disease Physician at the Westmead Hospital in Sydney, Australia. Ten of those patients also had infective endocarditis, with five of them having prosthetic valve endocarditis.